Recent progress and challenges in the discovery of new neuraminidase inhibitors

Bibliography

• Chand P. Recent advances in the discovery and synthesis of neuraminidase inhibitors. Expert Opin Ther Patents 2005;15:1009-25
   Web of Science ®Google Scholar
• Meijer A, Lackenby A, Hungnes O, Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007 – 08 season. Emerg Infect Dis 2009;15:552-60
   PubMed Web of Science ®Google Scholar
• Dawood FS, Jain S, Finelli L, Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15
   PubMed Web of Science ®Google Scholar
• Schunemann HJ, Hill SR, Kakad M, WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7:21-31
   PubMed Web of Science ®Google Scholar
• Earhart KC, Elsayed NM, Saad MD, Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2009;2:74-80
   PubMedGoogle Scholar
• de Jong MD, Thanh TT, Khanh TH, Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72
   PubMed Web of Science ®Google Scholar
• Le QM, Kiso M, Someya K, Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108
   PubMed Web of Science ®Google Scholar
• Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931-9
   PubMed Web of Science ®Google Scholar
• Das K, Aramini JM, Ma LC, Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010;17:530-8
   PubMed Web of Science ®Google Scholar
• von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007;6:967-74
   PubMed Web of Science ®Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73
   PubMed Web of Science ®Google Scholar
• Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 2006;71:372-8
   PubMed Web of Science ®Google Scholar
• Grienke U, Schmidtke M, von Grafenstein S, Influenza neuraminidase: a druggable target for natural products. Nat Prod Rep 2012;29:11-36
   PubMed Web of Science ®Google Scholar
• Chand P, Kotian PL, Dehghani A, Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent anti-influenza activity. J Med Chem 2001;44:4379-92
   PubMed Web of Science ®Google Scholar
• Grienke U, Schmidtke M, Kirchmair J, Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from alpinia katsumadai. J Med Chem 2009;53:778-86
   Google Scholar
• Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005;49:4515-20
   PubMed Web of Science ®Google Scholar
• Kongkamnerd J, Cappelletti L, Prandi A, Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. Bioorg Med Chem 2012;20:2152-7
   Google Scholar
• Kongkamnerd J, Milani A, Cattoli G, The quenching effect of flavonoids on 4-methylumbelliferone, a potential pitfall in fluorimetric neuraminidase inhibition assays. J Biomol Screen 2011;16:755-64
   PubMedGoogle Scholar
• Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002;12:159-66
   PubMed Web of Science ®Google Scholar
• Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol 2000;10:119-33
   PubMed Web of Science ®Google Scholar
• Rao A, Somayajulu D. Influenza classification from nucleotide sequence database. J Comput Sci Syst Biol 2011;4:77-80
   Google Scholar
• Air GM. Influenza neuraminidase. Influenza Other Respi Viruses 2012;6:245-56
   PubMed Web of Science ®Google Scholar
• Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11:134
   PubMed Web of Science ®Google Scholar
• Xie Y, Gong J, Li M, The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase. Curr Med Chem 2011;18:1050-66
   Google Scholar
• von Itzstein M, Thomson R. Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol 2009;189:111-54
   Google Scholar
• Gong J, Xu W. Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor. Curr Med Chem 2008;15:3145-59
   Google Scholar
• Liu Y, Zhang J, Xu W. Recent progress in rational drug design of neuraminidase inhibitors. Curr Med Chem 2007;14:2872-91
   PubMed Web of Science ®Google Scholar
• Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42
   PubMedGoogle Scholar
• Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86
   PubMed Web of Science ®Google Scholar
• Gong J, Xu W, Zhang J. Structure and functions of influenza virus neuraminidase. Curr Med Chem 2007;14:113-22
   PubMed Web of Science ®Google Scholar
• Johnson DS, Li JJ. In the art of drug synthesis. John Wiley and Sons; New Jersey: 2007
   Google Scholar
• Roberts NA, Govorkova EA. The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses. In: Mitrasinovic PM, editor, Global view of the fight against influenza. Nova Science, New York; 2009
   Google Scholar
• Mihajlovic ML, Mitrasinovic PM. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem 2008;136:152-8
   PubMed Web of Science ®Google Scholar
• Mihajlovic ML, Mitrasinovic PM. Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study. J Serb Chem Soc 2009;74:1-13
   Google Scholar
• Mihajlovic ML, Mitrasinovic PM. Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs). Mol Simul 2009;35:311-24
   Web of Science ®Google Scholar
• Govorkova EA, Leneva IA, Goloubeva OG, Comparison of efficacies of rwj-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45:2723-32
   PubMed Web of Science ®Google Scholar
• Mitrasinovic PM. Advances in the structure-based design of the influenza a neuraminidase inhibitors. Curr Drug Targets 2010;11:315-26
   PubMed Web of Science ®Google Scholar
• Russell RJ, Haire LF, Stevens DJ, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443:45-9
   PubMed Web of Science ®Google Scholar
• Amaro RE, Cheng X, Ivanov I, Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. J Am Chem Soc 2009;131:4702-9
   PubMed Web of Science ®Google Scholar
• Amaro RE, Swift RV, Votapka L, Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2011;2:388
   PubMed Web of Science ®Google Scholar
• Hussain Basha S, Prasad RN. In-silico screening of pleconaril and its novel substituted derivatives with neuraminidase of H1N1 influenza strain. BMC Res Notes 2012;5:105
   Google Scholar
• Venkatramani L, Johnson E, Kolavi G, Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6. BMC Struct Biol 2012;12:7
   Google Scholar
• Mitrasinovic PM. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem 2009;140:35-8
   PubMed Web of Science ®Google Scholar
• Rungrotmongkol T, Frecer V, De-Eknamkul W, Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 2009;82:51-8
   PubMed Web of Science ®Google Scholar
• Barnett JM, Cadman A, Gor D, Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87
   PubMed Web of Science ®Google Scholar
• Potier M, Mameli L, Belisle M, Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 1979;94:287-96
   PubMed Web of Science ®Google Scholar
• Nayak DP, Reichl U. Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. J Virol Methods 2004;122:9-15
   PubMed Web of Science ®Google Scholar
• Okomo-Adhiambo M, Hurt AC, Gubareva LV. The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Method Mol Biol 2012;865:95-113
   Google Scholar
• Buxton RC, Edwards B, Juo RR, Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000;280:291-300
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Sheu TG, Mishin VP, Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010;54:3671-7
   PubMed Web of Science ®Google Scholar
• Wetherall NT, Trivedi T, Zeller J, Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003;41:742-50
   PubMed Web of Science ®Google Scholar
• Liu AL, Wang HD, Lee SM, Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 2008;16:7141-7
   PubMed Web of Science ®Google Scholar
• Kongkamnerd J, Milani A, Cattoli G, A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. J Enzyme Inhib Med Chem 2012;27:5-11
   PubMed Web of Science ®Google Scholar
• Liu E-H, Qi L-W, Li P. Structural relationship and binding mechanism of five flavonoids with bovine serum albumin. Molecules 2010;15:9092-103
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhao N, Hu X, Tian J. Interaction of alpinetin with bovine serum albumin: probing the mechanism and binding site by spectroscopic methods. Spectrochimica Acta A 2010;76:410-17
   PubMed Web of Science ®Google Scholar
• Goncalves R, Mateus N, de Freitas V. Biological relevance of the interaction between procyanidines and trypsin: a multitechnique approach. J Agric Food Chem 2010;58:11924-31
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. J Am Med Assoc 2009;301:1066-9
   PubMed Web of Science ®Google Scholar
• von Itzstein M, Wu W-Y, Kok GB, Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23
   PubMed Web of Science ®Google Scholar
• Meindl P, Bodo G, Palese P, Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1974;58:457-63
   PubMed Web of Science ®Google Scholar
• Memoli MJ, Hrabal RJ, Hassantoufighi A, Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010;50:1252-5
   PubMed Web of Science ®Google Scholar
• Gaur AH, Bagga B, Barman S, Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010;362:88-9
   PubMed Web of Science ®Google Scholar
• Macdonald SJ, Cameron R, Demaine DA, Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 2005;48:2964-71
   PubMed Web of Science ®Google Scholar
• Watson KG, Cameron R, Fenton RJ, Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg Med Chem Lett 2004;14:1589-92
   PubMed Web of Science ®Google Scholar
• Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48:S3-S13
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tomozawa T, Kakuta M, CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53:186-92
   PubMed Web of Science ®Google Scholar
• TSRL, Inc. Neuraminidase inhibitors. WO2011123856; 2011
   Google Scholar
• Gomes P, Santos MI, Trigo MJ, Improved synthesis of amino acid and dipeptide chloromethyl esters using bromochloromethane. ChemInform 2003;34:1683-93
   Google Scholar
• Masuda T, Yoshida S, Arai M, Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-neu5Ac2en derivatives. Chem Pharm Bull 2003;51:1386-98
   PubMed Web of Science ®Google Scholar
• Sinica, Academia. Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses. WO2011143262; 2011
   Google Scholar
• Streicher H, Busse H. Building a successful structural motif into sialylmimetics-cyclohexenephosphonate monoesters as pseudo-sialosides with promising inhibitory properties. Bioorg Med Chem 2006;14:1047-57
   PubMed Web of Science ®Google Scholar
• Schug KA, Lindner W. Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosphonate and sulfonate residues. Chem Rev 2005;105:67-114
   PubMed Web of Science ®Google Scholar
• Shie J-J, Fang J-M, Lai P-T, A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. J Am Chem Soc 2011;133:17959-65
   PubMed Web of Science ®Google Scholar
• Kim CU, Lew W, Williams MA, Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997;119:681-90
   PubMed Web of Science ®Google Scholar
• Fuyuno I. Tamiflu side effects come under scrutiny. Nature 2007;446:358-9
   PubMedGoogle Scholar
• Kitching A, Roche A, Balasegaram S, Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)V, May 2009 – an internet-based cross-sectional survey. Eurosurveillance 2009;14:1-4
   Google Scholar
• Moscona A. Oseltamivir resistance, disabling our influenza defenses. N Engl J Med 2005;353:2633-6
   PubMed Web of Science ®Google Scholar
• Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328:1272-5
   PubMed Web of Science ®Google Scholar
• Karpf M, Trussardi R. New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu). J Org Chem 2001;66:2044-51
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche. Process for the preparation of 4,5-diamino shikimic acid derivatives. US20060047002; 2006
   Google Scholar
• Hoffmann-La Roche. Process from shikimic acid to oseltamivir phosphate. WO2009037137; 2009
   Google Scholar
• Rohloff JC, Kent KM, Postich MJ, Practical total synthesis of the anti-influenza drug GS-4104. J Org Chem 1998;63:4545-50
   Web of Science ®Google Scholar
• Karpf M, Trussardi R. Efficient access to oseltamivir phosphate (Tamiflu) via the O-trimesylate of shikimic acid ethyl ester. Angew Chem Int Ed Engl 2009;48:5760-2
   PubMed Web of Science ®Google Scholar
• Shibasaki M, Kanai M, Yamatsugu K. Recent development in synthetic strategies for oseltamivir phosphate. Isr J Chem 2011;51:316-28
   Google Scholar
• Sinica, Academia. Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity. WO2009029888; 2009
   Google Scholar
• Shie J-J, Fang J-M, Wang S-Y, Synthesis of Tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007;129:11892-3
   PubMed Web of Science ®Google Scholar
• Shie JJ, Fang JM, Wong CH. A concise and flexible synthesis of the potent anti-influenza agents Tamiflu and tamiphosphor. Angew Chem Int Ed Engl 2008;47:5788-91
   Google Scholar
• Babu YS, Chand P, Kotian PL. Influenza neuraminidase inhibitors as antiviral agents. Annu Rep Med Chem 2006;41:287-97
   Google Scholar
• Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expt Rev Anti infect Ther 2012;10:123-43
   PubMed Web of Science ®Google Scholar
• Biocryst Pharm., Inc. Substituted cyclopentane and cyclopentene compound useful as neuraminidase inhibitor. JP2011256196; 2010
   Google Scholar
• Mineno T, Miller MJ. Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents. J Org Chem 2003;68:6591-6
   PubMed Web of Science ®Google Scholar
• Peking University Shenzhen GRA. Polysubstituted five-membered ring small molecular compound used as influenza virus neuraminidase inhibitor. CN101486664; 2009
   Google Scholar
• Univ. Shandong. Thiazolidine neuraminidase inhibitor and application thereof. CN102146062; 2011
   Google Scholar
• Liu Y, Jing F, Xu Y, Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. Bioorg Med Chem 2011;19:2342-8
   PubMed Web of Science ®Google Scholar
• Nat. Defense Medical CT. 4,5-Diamino-3-halo-2-hydroxybenzoic acid derivatives and preparations thereof. US2012101157; 2012
   Google Scholar
• Singh S, Jedrzejas MJ, Air GM, Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction. J Med Chem 1995;38:3217-25
   PubMed Web of Science ®Google Scholar
• Feng E, Ye D, Li J, Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem 2012;7(9):1527-36
   PubMed Web of Science ®Google Scholar
• Univ. Hunan. Preparation method and medical application of 4-tert-butyl-6-phenyl-2-amino-6H-1,3-thiazine salt. CN101570521; 2009
   Google Scholar
• Univ. Hunan. 4-alkyl-6-aryl-5-alkoxy acyl 1,3-thiazine and preparation method and application thereof. CN101805312; 2010
   Google Scholar
• Univ. Hunan. 4-alkyl-6-aryl-2-acylamino-1,3-thiazine-5-formic ether, and preparation method and application thereof. CN101891705; 2010
   Google Scholar
• Univ. Hunan. Use of 4-alkyl-6-aryl-5-acetyl-1,3-thiazine for preparing neuraminidase inhibitor. CN102204914; 2011
   Google Scholar
• Xia L, Hu A, Cao G, Synthesis and crystal structure of 4-tert-butyl-6-(4-chlorophenyl)-3,6-dihydro-2H-1,3-thiazin-2-iminium chloride. Chinese J Struc Chem 2009;28:33-9
   Google Scholar
• Toyama Chemical Co., Ltd. Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination. EP2123276; 2009
   Google Scholar
• Univ. of Ryukyus, Bio System Consulting. Influenza virus neuraminidase inhibitor. JP2012077058; 2012
   Google Scholar
• Influmedix, Inc. Neuraminidase inhibitors and compositions and methods related thereto. US20110092557; 2011
   Google Scholar